InvestorsHub Logo
icon url

Whalatane

01/22/22 2:19 PM

#367057 RE: ralphey #367056

Ralphey. I assume U know what NNT is ....please advise if not ...Number Needed to Treat .

This is probably the best data out of R-IT ...US population

In this prespecified analysis of the 3146 patients en- rolled into REDUCE-IT in the United States, for the pri- mary composite end point there was a 31% relative risk reduction and 6.5% absolute risk reduction in first ischemic events (NNT, 15).
The key secondary com- posite end point of cardiovascular death, nonfatal MI, or nonfatal stroke was also reduced by 31%, with a 4.6% absolute risk reduction (NNT, 22).



Kiwi
icon url

rosemountbomber

01/22/22 2:25 PM

#367058 RE: ralphey #367056

For the sake of correctness, I believe you are not using the correct NTT numbers from R-I:

“Discussion
In this prespecified analysis of the 3146 patients enrolled into REDUCE-IT in the United States, for the primary composite end point there was a 31% relative risk reduction and 6.5% absolute risk reduction in first ischemic events (NNT, 15). The key secondary composite end point of cardiovascular death, nonfatal MI, or nonfatal stroke was also reduced by 31%, with a 4.6% absolute risk reduction (NNT, 22). Significant reductions in all composite and individual end points in the prespecified testing hierarchy were also observed, including cardiovascular death, MI, stroke, coronary revascularization, or hospitalization for unstable angina, as was the case with the overall trial results. In the US subgroup, there was an important, significant (P=0.004) 30% relative and 2.6% absolute risk reduction in all-cause mortality (NNT, 39), with an interaction P value of 0.02 between the US and non-US subgroups.”


https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.044440